Trial: 201911012

A Single-Arm, Open-Label, Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease after Peripheral Blood Hematopoietic Cell Transplantation

Phase

I

Principal Investigator

Schroeder, Mark

Disease Site

Hodgkin’s Lymphoma; Lymphoid Leukemia; Non-Hodgkin’s Lymphoma; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov